Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yuyu Pharma Inc. (000225:KRX), powered by AI.
Yuyu Pharma Inc. is currently trading at ₩3,875. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Yuyu Pharma Inc. on Alpha Lenz.
Yuyu Pharma Inc.'s P/E ratio is 1.1.
“Yuyu Pharma Inc. trades at a P/E of 1.1 (undervalued) with modest ROE of 6.4%.”
Ask for details →Yuyu Pharma Inc. is an established player in the healthcare industry, primarily engaged in the development, manufacture, and marketing of pharmaceutical products. The company's key function is to provide innovative treatments and therapeutic solutions, catering to various medical needs across sectors such as oncology, urology, and cardiovascular health. Yuyu Pharma Inc. also focuses on over-the-counter (OTC) medicines, enhancing accessibility for consumers seeking trusted healthcare products. With a commitment to research and development, the company continuously invests in discovering new drugs and improving existing formulations. This dedication not only strengthens their product portfolio but also reinforces their role as a pivotal entity in advancing public health care standards. Operating extensively within both local and international markets, Yuyu Pharma Inc. plays a significant role in the pharmaceutical supply chain, ensuring the availability of critical healthcare solutions worldwide. Founded in South Korea, the company leverages its strong regional roots while expanding its influence globally, contributing effectively to addressing diverse health challenges on a broad scale.
“Yuyu Pharma Inc. trades at a P/E of 1.1 (undervalued) with modest ROE of 6.4%.”
Ask for details →Yuyu Pharma Inc. (ticker: 000225) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 254 employees. Market cap is $8.8B.
The current price is ₩3,875 with a P/E ratio of 1.08x and P/B of 0.07x.
ROE is 6.40% and operating margin is 7.82%. Annual revenue is $140.9B.